Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-11-09

FDA Approved: OFEV — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for OFEV (nintedanib) submitted by Boehringer Ingelheim Pharmaceuticals, Inc., indicating an approved expanded indic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • OFEV (Nintedanib)

Snippet

SUPPL AP for OFEV (NINTEDANIB)